Imagene

"AI-based technology is slowly becoming interwoven within the everyday life and workflow of oncologists today." The revolution of AI within oncology is here. LungOI is the first AI-based Rapid Biomarker Profiling Laboratory Developed Test to identify actionable alterations in NSCLC patients. LungOI is a multi-gene biomarker test clinically available through our CLIA Certified Lab, providing test results in one day. DM us for more information on LungOI! #NSCLC #BiomarkerTesting #LungCancer #PrecisionMedicine #AIinHealthcare

Today, on World Lung Cancer Day, we acknowledge the reality that lung cancer remains the deadliest form of cancer worldwide. Despite significant advancements in treatment, a critical gap remains: too many patients are not receiving the essential molecular testing needed to access life-saving targeted therapies. At Imagene, we are committed to closing this gap. We developed LungOI, the first AI-powered biomarker profiling test, to support timely and informed clinical decisions. Our goal is to increase access to these vital tests, ensuring that more patients can benefit from the advances in precision medicine. This day serves as a reminder of the work still ahead. By expanding access to molecular testing, we can help to make progress, and hopefully improve outcomes for patients everywhere. #PrecisionOncology #LungCancer #WorldLungCancerDay #NSCLC #biomarkertesting

Lung Cancer Research Foundation published a new guide: "You do not need to be a doctor to understand your tumor. Biomarker testing can help" LungOI the first AI-powered biomarker profiling test for NSCLC can support timely informed clinical decisions. A Laboratory Developed Test available through our CLIA certified lab. DM us to learn more.

A great educational session on "The Importance of Waiting for Biomarker Results in NSCLC" LungOI is the first AI-based Rapid Biomarker Profiling Laboratory Developed Test to identify actionable alterations in NSCLC patients. LungOI is a multi-gene biomarker test including alterations in genes EGFR, ALK, ROS1, RET, NTRK1/2/3, ERBB2, BRAF, and MET. Clinically available through our CLIA Certified Lab, providing same-day results. DM us for more information on LungOI! #NSCLC #BiomarkerTesting #LungCancer #PrecisionMedicine #AIinHealthcare https://lnkd.in/e3AkHCFf

A new article in Calcalist (Hebrew) telling the Imagene story and details our Oncology Intelligence: Vision Foundation Model Engine designed to decode cancer from biopsy images. This State-of-the-Art Foundation Model facilitates the development of unlimited downstream research applications beyond biomarker profiling, including predicting treatment responses, disease prognosis, and discovering novel biomarkers through the identification of pathological features. #foundationmodel #oncologyintelligence #OCI Oracle Cloud https://lnkd.in/e_QsFVxg

Thank you Rachel Dangur for acknowledging our talk. Indeed Imagene's Oncology Intelligence engine powered by Oracle holds the power to transform cancer diagnosis, research and care #precisiononcology #OCI #oncologyintelligence

It was great to be on stage with Omri Stone, Oracle at "The Future of AI" conference, discussing the importance of AI in cancer diagnosis and research. Imagene #precisiononcology #oncologyintelligence #OCI

The recent article in The Lancet, "Lung cancer treatment: 20 years of progress," underscores the remarkable advancements in lung cancer therapies over the past two decades, bringing new hope with targeted treatments and precision medicine. Despite these breakthroughs, a significant number of patients worldwide are still not benefiting from these innovations due to limited access to diagnostic testing. At Imagene AI, we recognize the crucial need for molecular testing and biomarker profiling to ensure patients receive the best possible care. Our rapid AI-based NSCLC biomarker test, LungOI, is designed to bridge this gap by providing quick and accurate results. Additionally, our Oncology Intelligence: Vision Foundation Model Engine is specifically designed to decode cancer from biopsy images, facilitating the development of unlimited downstream research applications, including predicting treatment responses and disease prognosis as well as discovering novel biomarkers through the identification of pathological features. It's essential to address the disparity in access to these life-saving technologies. We are committed to advancing genomics for all, ensuring that more patients can benefit from the latest advancements in cancer treatment. #precsionmedicine #biomarkers #cancerresearch https://lnkd.in/e_jT-CsE 

Congratulations to Prof. Christian Rolfo, MD, PhD, MBA,Dr.h.c. on his appointment as Director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center (OSUCCC – James). We are proud to have such an accomplished leader and expert on Imagene AI's scientific advisory board. Your contributions to oncology and precision medicine continue to inspire us all! https://lnkd.in/eTVsvDse #Oncology #Leadership #CancerResearch

Great to have you onboard Jessica Riley Indeed amazing 3 days, and many more to come!